Fabrication of vitamin B₁₂-loaded multivesicular liposomes via microfluidic double-emulsification: Extended pharmacokinetics and bioavailability.

Authors

Rui Chang, Yu Lu, Yiming Liu, Qian Gao, Xuewei Zhang, Yanan Zhang, Yutong Xing, Xue Yan, Chaoxing He, Huifeng Zhang, Bai Xiang

Published in

International journal of pharmaceutics: X. Volume 12. Pages 100659. Epub Sep 03, 2026.

Abstract

Vitamin B₁₂ (VB₁₂) is essential for treating pediatric methylmalonic acidemia (MMA) by activating methylmalonyl-CoA mutase and reducing toxic metabolite levels. However, its clinical utility is constrained by frequent intramuscular injections (leading to poor compliance) and the low, highly variable bioavailability associated with oral administration. Thus, a long-acting, sustained-release VB₁₂ system is urgently needed. Herein, VB₁₂-loaded multivesicular liposomes (VB₁₂-MVLs) were reported for the first time, prepared via an improved microfluidic-double emulsification method. To overcome the loading limitation imposed by VB₁₂'s water solubility, dimethyl-β-cyclodextrin (DM-β-CD) was introduced to construct VB₁₂-β-MVLs. The resulting VB₁₂-MVLs exhibited a characteristic multi-chambered "honeycomb" structure with uniform size (D₅₀ ∼ 14.30 μm) and high encapsulation efficiency (92.43%). DM-β-CD significantly increased the drug concentration from 10.96 to 17.60 mg mL^-1. In vivo studies showed that the lipid phase remained at the subcutaneous injection site for >4 days, while the aqueous phase sustained release for up to 7 days. Pharmacokinetic analysis revealed that compared with free VB₁₂ (mean residence time, MRT = 1.50 h), VB₁₂-MVLs extended MRT to 80.69 h, and VB₁₂-β-MVLs further extended it to 121.42 h, with a relative bioavailability of 191.89%. Preliminary safety evaluations indicated no hemolysis, minimal tissue irritation, and no significant changes in hematological or serum biochemical indices. Collectively, the VB₁₂-MVLs platform-particularly VB₁₂-β-MVLs formulation-represents a promising long-acting formulation for MMA, with the potential to reduce dosing frequency and improve the quality of life of pediatric patients while maintaining therapeutic efficacy.

PMID:
42740914
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.